Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular & Oncology Development.
TarMart Solution Ecosystem & Related Targets
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery & Antigen | Full-length EDNRA Lentivirus / Promise-ORF – For stable cell line generation and native GPCR conformational presentation. High titer (>10^8 TU/mL), CMV promoter, Puromycin selection. Sequence Verified. | View EDNRA Products |
| Benchmark Antibody | Anti-EDNRA Antagonist Mimetic – Recombinant rabbit monoclonal, binding domain mapped to N-terminal. Positive control for blocking assays. Also available as anti-EDNRA benchmark antibody for assay standardization. | View EDNRA Products |
| Knockdown Validator | EDNRA siRNA Set (3 target-specific + 1 control) – For specificity verification in functional assays. >85% knockdown efficiency validated. | View EDNRA Products |
| Counter-Screen (EDNRB) | EDNRB Lentivirus Premade Particles – For selectivity validation vs. ETB receptor. Critical for safety profiling to avoid EDNRB-mediated toxicity. | View EDNRB Products |
| Endogenous Ligand | ET-1 (Endothelin-1) – Natural ligand for binding and competitive assays, cell functional activation control. | View ET-1 Products |
| Pathway Upstream | ECE1 (Endothelin Converting Enzyme 1) – Recombinant protein for enzymatic cascade studies, ET-1 generation pathway. | View ECE1 Products |
| Additional Ligand Control | EDN3 (Endothelin 3) – Ligand control for binding specificity studies. Native sequence. | View EDN3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| EDNRA/EDNRB Selectivity Screening (Safety Critical) | Matched Lentivirus Pair expressing EDNRA vs. EDNRB with identical promoters/tags. Enables parallel binding assays under native conformation. |
| GPCR Conformational Preservation | Lentivirus-delivered stable cell lines in HEK293 background. Preserves 7-TM topology and G-protein coupling for calcium flux assays. |
| Assay Standardization & Specificity Control | Recombinant Benchmark Antibodies included for standardizing assays. Validated siRNA set for target-specific knockdown to eliminate off-target artifacts. |
| High-Throughput Reproducibility | Premade particles with defined MOI protocols. Consistent expression levels across batches (CV < 15%). |
| False Positive Mitigation in Functional Assays | Validated siRNA included for background specificity checks; includes scrambled control. |
Live EDNRA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The EDNRA-targeting therapeutic landscape is dominated by small-molecule antagonists for Pulmonary Arterial Hypertension (PAH), with Ambrisentan (Gilead) and Macitentan (Actelion/J&J) representing standards of care. The field is witnessing a strategic pivot toward oncology applications, particularly in prostate cancer, renal cell carcinoma, and breast cancer, where EDNRA signaling drives tumor angiogenesis, proliferation, and metastasis. In fibrotic diseases such as scleroderma and chronic kidney disease, the endothelin axis plays a key role in pathological tissue remodeling.
The race for next-generation EDNRA therapeutics is intensifying. While first-generation therapies face generic competition, major players are shifting from non-selective dual antagonists to highly EDNRA-selective inhibitors to minimize edema and hepatic toxicity associated with EDNRB blockade. The next wave of R&D includes combination regimens with PD-1 inhibitors, long-acting biologics (mAbs), and novel modalities such as macrocyclic inhibitors and RNA-based therapeutics (siRNA/mRNA) for fibrosis.
Key Mutations and Disease Associations
EDNRA mutations are linked to human diseases, highlighting the receptor's functional importance:
- rs786205230 (MFDA): Mutation in EDNRA associated with Multiple Functional Deficiency of Adipose (MFDA). Evidence: UniProt P25101 VAR_073788.
- rs876657388 (MFDA): Another MFDA-associated mutation. Evidence: UniProt P25101 VAR_073789.
- Somatic mutation in breast cancer: A somatic mutation identified in a breast cancer sample. Evidence: UniProt P25101 VAR_035758.
These mutations underscore the need for robust assay systems to study EDNRA function in both inherited and acquired conditions.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist | Gilead, Actelion (J&J), Novartis, Phathom | PAH, Hypertension, Scleroderma | Selectivity Assay vs. EDNRB (Need matched Lentivirus cell lines) |
| Monoclonal Antibody | Emerging Biotechs | Oncology, Fibrosis | Binding Assays (Need high-titer Lentivirus for flow cytometry) |
| Peptide Antagonists | Various Biotechs | PAH, Heart Failure, Chronic Kidney Disease | Binding Kinetics (Need high-expression EDNRA stable cells) |
| Macrocyclic Inhibitors | Preclinical | Solid Tumors | Internalization & Trafficking Assays (Live-cell imaging compatible) |
| RNA-based (siRNA/mRNA) | Early Development | Fibrosis | Knockdown Efficiency Validation (Need validated siRNA controls) |